SOURCES SOUGHT
66 -- Vapor Inhalation System
- Notice Date
- 7/28/2017
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- HHS-NIH-NIDA-SSSA-SBSS-2017-636
- Archive Date
- 8/22/2017
- Point of Contact
- Sneha V Singh, Phone: 3014802443
- E-Mail Address
-
sneha.singh@nih.gov
(sneha.singh@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- SOLICITATION NUMBER: HHS-NIH-NIDA-SSSA-SBSS-2017-636 Title: Vapor Inhalation System Classification Code: 6640 NAICS Code: 334516 Description: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. BACKGROUND Animal models of passive nicotine delivery vary in advantages and disadvantages. The most common include chronic minipump implantation, nicotine delivery through drinking water, and chronic injections. Chronic minipumps offer the advantage of chronic delivery with only one invasive procedure of a controlled dose of a nicotine. However, they require multiple surgeries in order to accommodate longer administration periods (through pump replacement) and can only delivery nicotine on a chronic sustained basis, not accounting for changes in body weight over time. Nicotine delivery through the drinking water replaces standard drinking water with nicotine, allowing nicotine to be delivered whenever an animal drinks, which is typically in larger quantities during their active phase, mimicking human smoking behavior. However, because rodents remain in charge or their nicotine delivery, it is difficult to control dosage as well as requires adding saccharin or other sweet substances to accommodate for the bitter taste of nicotine. Finally, chronic injections of nicotine include multiple intraperitoneal (i.p.) injections of nicotine, multiple times a day to mimic human smoking behavior. Chronic injections increase the potential risk for infection or visceral damage as well as increase the handling stress associated with multiple injections per day. Nicotine vapor delivery has been used and established to show blood nicotine levels that are comparable to human cigarette smoking. Vapor delivery overcomes all of the shortcomings of the abovementioned methods: i) it does not require any surgeries; ii) dosage can be precisely controlled and can be accommodated to fluctuating body weight; iii) nicotine can be delivered through sustained delivery or pulsatile delivery, all over the course of multiple hours or days; iv) it does not require training or acclimation; v) it does not increase the risk for infection; and vi) it minimizes handling stress since it does not require multiple injections. As well, it more precisely mimics human cigarette smoking or e-cigarette vaping, given the same route of administration (inhalation). Finally, often, nicotine is co-administered with flavors or additives (for ex: menthol) in cigarettes and e-cigarettes, which can be included for simultaneous delivery of nicotine vapor. Thus, the use of the vapor chambers is integral to the development of a preclinical model of human smoking with high face validity. Using this method in combination with our standard imaging protocols will offer a unique insight into nicotine addiction and dependence. PURPOSE AND OBJECTIVES The purpose of this acquisition is to acquire a vapor delivery system. PROJECT REQUIREMENTS Two (2) passive e-Vape inhalation chambers (4 chambers in each set) with a two-day onsite training and crafting and shipping costs. • Customizable drug delivery (drug, dosage and frequency) of vapor • Precisely mimic human e-cigarette vaping of nicotine • Can delivery multiple drugs simultaneously (for ex: nicotine and menthol) • Mimic long-term laboratory housing, with the inclusion of bedding, food and water freely available • Minimizing stress of drug delivery (i.e. does not require surgery or multiple injections) • Minimizes experimenter exposure to the vapor through active filtration and use of the institutional exhaust system Period of Performance: The anticipated delivery date for this acquisition is 60 days from date of award. Onsite training is to be provided within 2 weeks of delivery. Capability statement: Contractors that believe they possess the ability to provide the required services should submit documentation of their ability to meet each of the project requirements to the Contract Specialist. The capability statement should include 1) the total number of employees, 2) documentation of ability to provide the required support, 3) any contractor GSA Schedule contracts by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Contractors must also provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested organizations are required to identify their type of business, applicable North American Industry Classification System Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. All capability statements sent in response to this Sources Sought Notice must be submitted to Sneha Singh, Contract Specialist, via email at sneha.singh@nih.gov before the closing date and time of this announcement. All responses must be received by the specified due date and time in order to be considered. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SBSS-2017-636/listing.html)
- Record
- SN04602582-W 20170730/170728231721-48ea5641c67b119118746b059faa26c6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |